A patient on 3 mg oral semaglutide (Rybelsus) is switching to oral semaglutide (Wegovy); what should the next dose be?

Switching from Rybelsus 3 mg to Oral Wegovy: Next Dose Recommendation

There is no FDA-approved oral formulation of Wegovy; Wegovy is only available as a subcutaneous injection, while Rybelsus is the oral semaglutide formulation approved for type 2 diabetes. If you are switching from oral Rybelsus 3 mg to injectable Wegovy for weight management, the next dose should be 0.25 mg subcutaneously once weekly for 4 weeks, then escalate to 0.5 mg weekly. 1, 2

Critical Clarification: Oral vs Injectable Formulations

• Rybelsus is the oral semaglutide formulation approved for type 2 diabetes at doses of 3 mg, 7 mg, and 14 mg daily. 3
• Wegovy is the subcutaneous (injectable) semaglutide formulation approved for chronic weight management at a maintenance dose of 2.4 mg weekly. 4
• No oral Wegovy exists: The FDA has not approved an oral formulation marketed as "Wegovy pills." 3
• Oral semaglutide for obesity at higher doses (25 mg and 50 mg daily) has been studied in clinical trials (OASIS-1) but is not yet FDA-approved. 4, 5

If Switching to Injectable Wegovy (Subcutaneous)

Recommended Titration Schedule

Start from the beginning of the Wegovy titration protocol regardless of prior Rybelsus dose, as the pharmacokinetics and bioavailability differ substantially between oral and subcutaneous formulations. 1, 2

• Weeks 1–4: 0.25 mg subcutaneously once weekly 1, 2
• Weeks 5–8: 0.5 mg subcutaneously once weekly 1, 2
• Weeks 9–12: 1.0 mg subcutaneously once weekly 1, 2
• Weeks 13–16: 1.7 mg subcutaneously once weekly 1, 2
• Week 17 onward: 2.4 mg subcutaneously once weekly (maintenance dose) 1, 2

Rationale for Starting at 0.25 mg

• The 0.25 mg dose is not therapeutic but serves to minimize gastrointestinal adverse events (nausea occurs in ~40% of patients, vomiting in ~16%). 1, 2
• Gradual dose escalation significantly reduces GI side effects compared to rapid titration. 4, 2
• Oral and subcutaneous semaglutide are not bioequivalent: Oral semaglutide has ~1% bioavailability due to first-pass metabolism, while subcutaneous administration bypasses this entirely. 6
• No direct dose conversion exists between Rybelsus and Wegovy; restarting the titration protocol is the safest approach. 3

If Considering Higher-Dose Oral Semaglutide (Not FDA-Approved)

Investigational Oral Semaglutide for Obesity

• Oral semaglutide 50 mg daily achieved a mean weight reduction of 15.1% at 68 weeks in the OASIS-1 trial, compared to 2.4% with placebo. 5
• Titration for 50 mg oral semaglutide (investigational):
  • Start at 3 mg daily for 4 weeks
  • Increase to 7 mg daily for 4 weeks
  • Increase to 14 mg daily for 4 weeks
  • Increase to 25 mg daily for 4 weeks
  • Increase to 50 mg daily (maintenance) 5
• This formulation is not FDA-approved and is not available for clinical use outside of research settings. 5

Key Administration Differences

Rybelsus (Oral) Administration

• Take on an empty stomach upon waking with no more than 120 mL (4 oz) of plain water. 3
• Wait at least 30 minutes before eating, drinking, or taking other oral medications. 3
• Food and excess liquid reduce absorption by up to 88% if taken with meals or large volumes of water. 6

Wegovy (Subcutaneous) Administration

• Inject once weekly at any time of day, with or without meals. 1, 2
• No fasting or timing restrictions relative to food intake. 1, 2

Common Pitfalls to Avoid

• Do not assume dose equivalence: A patient on Rybelsus 3 mg daily is not equivalent to any specific Wegovy dose; restart the titration protocol. 1, 2, 3
• Do not skip the 0.25 mg starter dose: This increases the risk of severe nausea and treatment discontinuation (12% discontinued in real-world studies due to GI side effects). 7
• Do not confuse formulations: Rybelsus and Wegovy contain the same active ingredient (semaglutide) but are not interchangeable due to different routes of administration and approved indications. 3
• Individual strengths are not substitutable on a mg-to-mg basis: FDA labeling explicitly warns against direct dose conversion between formulations. 3

Monitoring and Follow-Up

• Assess tolerance at each dose escalation: If GI symptoms are intolerable, delay the next dose increase by 4 weeks. 1, 2
• Evaluate weight loss response: If <5% weight loss is achieved by week 16 on Wegovy, consider discontinuation or alternative therapies. 4
• Screen for contraindications: Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN 2), or prior serious hypersensitivity to semaglutide. 1, 2